Success Story: Fast-Track EB1A Success! Our Expert Team Helped an Assistant Professor Win Approval in Only 13 Days with Premium Processing

Client’s Testimonial:

“Exceptional Team that puts the client’s needs first. Efficacious, prompt, and professional. They do care!”

On March 5^th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for an Assistant Professor in the Field of Clinical Medicine (Approval Notice).

General Field: Clinical Medicine

Position at the Time of Case Filing: Assistant Professor of Medicine

Approval Notice Date: March 5^th, 2025

Processing Time: 13 days (Premium Processing Requested)

Case Summary:

The North America Immigration Law Group (NAILG) is pleased to announce the rapid approval of an I-140 petition for an Alien of Extraordinary Ability (EB-1A) for a highly accomplished expert in clinical medicine specializing in infectious diseases. The petition received a favorable decision in just 13 days, underscoring the exceptional and nationally significant contributions of this individual.

Our client, who holds an M.D. and M.P.H. degree, is an established leader in the field of Medicine. Their proposed endeavor is centered on advancing clinical research to develop novel prevention and management strategies for a wide range of infectious diseases. This vital work directly addresses critical public health challenges and seeks to improve patient outcomes.

To demonstrate the client’s sustained national or international acclaim and their position among the elite in their field, our legal team presented comprehensive evidence, highlighting:

Extensive Publication Record: The client has an impressive publication record, including more than 50 peer-reviewed journal articles, with more than 20 as first-authored contributions, and 6 book chapters, 5 of which are first-authored. These works appear in highly-regarded academic and clinical publications.
Profound Research Influence: Their research in clinical medicine has been cited more than 500 times, according to Google Scholar. This high citation count demonstrates the widespread reliance on and influence of their work by other researchers and clinicians globally.
Active Peer Reviewer: The client has conducted nearly 50 reviews for various academic journals, a testament to their recognized expertise and their significant role in evaluating cutting-edge research in their field.
Original Scientific Contributions: The petition highlighted the client’s major original scientific contributions, including significant advancements in improving diagnostic methods for infectious diseases, developing effective treatment strategies, and influencing clinical guidelines and practices.
Invited Speaker: The client has also received unsolicited invitations to speak at symposia and present their research, signifying their reputation as a sought-after expert whose insights are valued by peers.

The petition was strongly supported by four letters of recommendation from leading experts in the field of clinical medicine. These letters unequivocally affirmed the client’s extraordinary ability and the critical impact of their contributions to global public health.

Through a meticulously prepared petition that showcased their consistent record of success and influence, NAILG successfully demonstrated that our client meets the stringent criteria for an EB-1A classification. This rapid approval is a testament to the client’s exceptional talent and their vital role in advancing medical science and protecting public health in the United States.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.